REMAP-CAP and RECOVERY trials...a little background... So, the REMAP-CAP study published on January 9th set out to determine if the IL-6 receptor antagonists, tocilizumab and Sarilumab, compared with standard care, improve respiratory and cardiovascular organ support free days up…